Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests
Bionano Genomics, Inc. (BNGO)
Last bionano genomics, inc. earnings: 8/8 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the University of Iowa Hospitals and Clinics (UIHC) will switch their method of clinical molecular testing for patients with presumed Facioscapulohumeral Muscular Dystrophy (FSHD) to optical mapping using Bionano’s Saphyr System. The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD. Following this evaluation, the UIHC is implementing this month a Saphyr-based assay into its clinical testing workflow. FSHD affects approximately 1 in 10,000 individuals in the United States. It is usually caused by deletion or loss of DNA in a section of chromosome 4 shortening a critical repeat element, the D4Z4 repeat, that plays an essential role in regulating the expression of the DUX4 gene. One component of genetically confirming a diagnosis of FSHD is measuring the exact number of D4Z4 repeats. The Molecular Pathology
Show less
Read more
Impact Snapshot
Event Time:
BNGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNGO alerts
High impacting Bionano Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
BNGO
News
- Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies [Yahoo! Finance]Yahoo! Finance
- Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic MalignanciesGlobeNewswire
- Bionano Genomics (NASDAQ:BNGO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Bionano Genomics (NASDAQ:BNGO) had its "sell (e)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Earnings To Watch: Bionano Genomics Inc (BNGO) Reports Q3 2025 Result [Yahoo! Finance]Yahoo! Finance
BNGO
Analyst Actions
- 11/24/25 - HC Wainwright
BNGO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- BNGO's page on the SEC website